These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 28061552)

  • 81. Immunotherapy approaches targeting neuroblastoma.
    Nguyen R; Thiele CJ
    Curr Opin Pediatr; 2021 Feb; 33(1):19-25. PubMed ID: 33315686
    [TBL] [Abstract][Full Text] [Related]  

  • 82. Natural Killer Cells to the Attack: Combination Therapy against Neuroblastoma.
    Zenarruzabeitia O; Vitallé J; Astigarraga I; Borrego F
    Clin Cancer Res; 2017 Feb; 23(3):615-617. PubMed ID: 27872101
    [TBL] [Abstract][Full Text] [Related]  

  • 83. Isolation and structural analysis of peptide mimotopes for the disialoganglioside GD2, a neuroblastoma tumor antigen.
    Förster-Waldl E; Riemer AB; Dehof AK; Neumann D; Brämswig K; Boltz-Nitulescu G; Pehamberger H; Zielinski CC; Scheiner O; Pollak A; Lode H; Jensen-Jarolim E
    Mol Immunol; 2005 Feb; 42(3):319-25. PubMed ID: 15589320
    [TBL] [Abstract][Full Text] [Related]  

  • 84. A pilot study of genomic-guided induction therapy followed by immunotherapy with difluoromethylornithine maintenance for high-risk neuroblastoma.
    Kraveka JM; Lewis EC; Bergendahl G; Ferguson W; Oesterheld J; Kim E; Nagulapally AB; Dykema KJ; Brown VI; Roberts WD; Mitchell D; Eslin D; Hanson D; Isakoff MS; Wada RK; Harrod VL; Rawwas J; Hanna G; Hendricks WPD; Byron SA; Snuderl M; Serrano J; Trent JM; Saulnier Sholler GL
    Cancer Rep (Hoboken); 2022 Nov; 5(11):e1616. PubMed ID: 35355452
    [TBL] [Abstract][Full Text] [Related]  

  • 85. Treatment of Transient Peripheral Neuropathy During Chimeric 14.18 Antibody Therapy in Children With Neuroblastoma: A Case Series.
    Ari P; Kars M; Meany H; Pestieau S
    J Pediatr Hematol Oncol; 2018 Mar; 40(2):e113-e116. PubMed ID: 28678088
    [TBL] [Abstract][Full Text] [Related]  

  • 86. Clinical Phenotype and Management of Severe Neurotoxicity Observed in Patients with Neuroblastoma Treated with Dinutuximab Beta in Clinical Trials.
    Wieczorek A; Manzitti C; Garaventa A; Gray J; Papadakis V; Valteau-Couanet D; Zachwieja K; Poetschger U; Pribill I; Fiedler S; Ladenstein R; Lode HN
    Cancers (Basel); 2022 Apr; 14(8):. PubMed ID: 35454826
    [TBL] [Abstract][Full Text] [Related]  

  • 87. [Nursing care for a child with recurrent neuroblastoma treated with immunotherapy].
    Mast C
    Kinderkrankenschwester; 2012 Apr; 31(4):142-4. PubMed ID: 22594170
    [No Abstract]   [Full Text] [Related]  

  • 88. A phase I clinical trial of the hu14.18-IL2 (EMD 273063) as a treatment for children with refractory or recurrent neuroblastoma and melanoma: a study of the Children's Oncology Group.
    Osenga KL; Hank JA; Albertini MR; Gan J; Sternberg AG; Eickhoff J; Seeger RC; Matthay KK; Reynolds CP; Twist C; Krailo M; Adamson PC; Reisfeld RA; Gillies SD; Sondel PM;
    Clin Cancer Res; 2006 Mar; 12(6):1750-9. PubMed ID: 16551859
    [TBL] [Abstract][Full Text] [Related]  

  • 89. The GD2-specific 14G2a monoclonal antibody induces apoptosis and enhances cytotoxicity of chemotherapeutic drugs in IMR-32 human neuroblastoma cells.
    Kowalczyk A; Gil M; Horwacik I; Odrowaz Z; Kozbor D; Rokita H
    Cancer Lett; 2009 Aug; 281(2):171-82. PubMed ID: 19339105
    [TBL] [Abstract][Full Text] [Related]  

  • 90. Inflammatory response and treatment tolerance of long-term infusion of the anti-GD
    Ceylan K; Jahns LJ; Lode BN; Ehlert K; Kietz S; Troschke-Meurer S; Siebert N; Lode HN
    Pediatr Blood Cancer; 2018 Jun; 65(6):e26967. PubMed ID: 29350486
    [TBL] [Abstract][Full Text] [Related]  

  • 91. Guidelines for outpatient administration of naxitamab: Experience from Atrium Health Levine Children's Hospital.
    Trovillion EM; Michael M; Jordan CC; Brown L; Phillips K; Oesterheld J; Saulnier-Sholler G
    Cancer Med; 2024 Feb; 13(3):e7045. PubMed ID: 38396377
    [TBL] [Abstract][Full Text] [Related]  

  • 92. Topotecan plus cyclophosphamide as maintenance chemotherapy for children with high-risk neuroblastoma in complete remission: short-term curative effects and toxicity.
    Feng C; Tang S; Wang J; Liu Y; Yang G
    Nan Fang Yi Ke Da Xue Xue Bao; 2013 Aug; 33(8):1107-10. PubMed ID: 23996746
    [TBL] [Abstract][Full Text] [Related]  

  • 93. Pharmacokinetics of the chimeric anti-GD2 antibody, ch14.18, in children with high-risk neuroblastoma.
    Desai AV; Fox E; Smith LM; Lim AP; Maris JM; Balis FM
    Cancer Chemother Pharmacol; 2014 Nov; 74(5):1047-55. PubMed ID: 25212536
    [TBL] [Abstract][Full Text] [Related]  

  • 94. Antitumor Activity and Tolerability of hu14.18-IL2 with GMCSF and Isotretinoin in Recurrent or Refractory Neuroblastoma: A Children's Oncology Group Phase II Study.
    Shusterman S; Naranjo A; Van Ryn C; Hank JA; Parisi MT; Shulkin BL; Servaes S; London WB; Shimada H; Gan J; Gillies SD; Maris JM; Park JR; Sondel PM
    Clin Cancer Res; 2019 Oct; 25(20):6044-6051. PubMed ID: 31358541
    [TBL] [Abstract][Full Text] [Related]  

  • 95. Investigation of the Role of Dinutuximab Beta-Based Immunotherapy in the SIOPEN High-Risk Neuroblastoma 1 Trial (HR-NBL1).
    Ladenstein R; Pötschger U; Valteau-Couanet D; Luksch R; Castel V; Ash S; Laureys G; Brock P; Michon JM; Owens C; Trahair T; Chi Fung Chan G; Ruud E; Schroeder H; Beck-Popovic M; Schreier G; Loibner H; Ambros P; Holmes K; Castellani MR; Gaze MN; Garaventa A; Pearson ADJ; Lode HN
    Cancers (Basel); 2020 Jan; 12(2):. PubMed ID: 32013055
    [TBL] [Abstract][Full Text] [Related]  

  • 96. Pharmacokinetics and pharmacodynamics of ch14.18/CHO in relapsed/refractory high-risk neuroblastoma patients treated by long-term infusion in combination with IL-2.
    Siebert N; Eger C; Seidel D; Jüttner M; Zumpe M; Wegner D; Kietz S; Ehlert K; Veal GJ; Siegmund W; Weiss M; Loibner H; Ladenstein R; Lode HN
    MAbs; 2016; 8(3):604-16. PubMed ID: 26785755
    [TBL] [Abstract][Full Text] [Related]  

  • 97. Immunotherapeutic strategies in neuroblastoma: antitumoral activity of deglycosylated Ricin A conjugated anti-GD2 antibodies and anti-CD3xanti-GD2 bispecific antibodies.
    Manzke O; Russello O; Leenen C; Diehl V; Bohlen H; Berthold F
    Med Pediatr Oncol; 2001 Jan; 36(1):185-9. PubMed ID: 11464879
    [TBL] [Abstract][Full Text] [Related]  

  • 98. Bilateral tonic pupils secondary to anti-GD2 antibody therapy for neuroblastoma.
    Edwards CM; Elefant D; Isakoff MS; Gaffar MA
    J AAPOS; 2024 Apr; 28(2):103852. PubMed ID: 38368925
    [TBL] [Abstract][Full Text] [Related]  

  • 99. Combination therapy with interleukin-2 and antitumor monoclonal antibodies.
    Sondel PM; Hank JA
    Cancer J Sci Am; 1997 Dec; 3 Suppl 1():S121-7. PubMed ID: 9457407
    [TBL] [Abstract][Full Text] [Related]  

  • 100. Disparities in the use of antineoplastic immunotherapy in pediatric malignant adrenal tumors.
    Shoag JM; Podda A; Kobetz EN
    Pediatr Blood Cancer; 2020 Sep; 67(9):e28522. PubMed ID: 32614121
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.